PLK1 inhibition induces cancer cell death while also upregulating PD-L1 expression of surviving cancer cells, thereby providing the opportunity to target surviving cancer with PD-L1 antibody-conjugated nanoparticles (benefiting cancer otherwise having no established receptors for drug delivery). This evidence concerns the gene CD274 and cancer.